Clinical Trials Logo

Clinical Trial Summary

The aims of the study are to compare the recovering period between a group of patients with conventional sedation, a group using hypnosis as sedation during the surgery and a third group using hypnosis as a relaxation method and preparation but enjoying a classic sedation for their surgery. Comparaison of pain ( different types of pain), consumption of pain killers ,anxiety and fatigue on day0,1, 8 after surgery and every. 3 months during the first 2 years of follow up. Comparisons are also performed in substudies defined by treatments modalités. Inflammatory parameters s ( CRP_ C reactive protein, NLR- ( neutrophils to lymphocyte ratio) are measured on Day 0, 1, 8 and also salivary Immunoglobulins and different endocannabinoids.


Clinical Trial Description

Hypnosis has already demonstrated benefits among breast cancer patients undergoing oncologic surgery. Different side effects were measured during the post operative period and at each follow up visit by physicians in order to carefully compare side effects in the 3 armes of patients.. Our hypothesis was that hypnosis sedation generates less perioperative inflammatory reaction. A substudy of 50 patients was also dedicated to the investigation ofsalivary immunoglobulins and dosage of differents endocannabinoids ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03330717
Study type Interventional
Source Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Contact
Status Completed
Phase N/A
Start date November 15, 2017
Completion date December 31, 2019

See also
  Status Clinical Trial Phase
Completed NCT03273426 - Prediction of pCR by Preoperative Biopsy in Breast Cancer With cCR After Neoadjuvant Chemotherapy. N/A
Recruiting NCT04583124 - Adjusting the Dose of Therapeutic Exercise to Prevent Neurotoxicity Due to Anticancer Treatment (ATENTO) N/A
Recruiting NCT04489173 - TAS102 in Patients With ER-positive, HER2-negative Advanced Breast Cancer Phase 2
Recruiting NCT02913573 - Effect of Pectoral Nerve Block on Post-op Pain in Patients Undergoing Mastectomy and Immediate Reconstruction Phase 2
Completed NCT03124095 - Combined Training Intervention for Women Who Underwent Primary Treatment for Breast Cancer N/A
Terminated NCT00251095 - Comparison of Safety and Efficacy of TOCOSOL(R) Paclitaxel Versus Taxol(R) for Treatment of Metastatic Breast Cancer Phase 3
Completed NCT05576545 - Develop and Evaluate the Effectiveness of a Self-Care Smartphone Application on the Self-Efficacy, and Resilience Among Newly Diagnosed Breast Cancer Patients Undergoing Treatment N/A
Active, not recruiting NCT03625635 - Effect of a Clinical Nutrition Intervention Program in Breast Cancer Patients During Antineoplastic Treatment N/A
Recruiting NCT04799535 - Quantitative Microvasculature Imaging for Breast Cancer Detection and Monitoring
Withdrawn NCT03266562 - Estrogen Receptor Expression in Breast Cancer - Assessed With Positron Emission Mammography N/A
Completed NCT00530868 - Comparing Letrozole Given Alone to Letrozole Given With Avastin in Post-Menopausal Women Breast Cancer Phase 2
Recruiting NCT06255808 - Development of Assist Tool for Breast Examination Using the Principle of Ultrasonic Sensor
Completed NCT04640220 - Improvement of Range of Motion in Frozen Shoulder in Breast Cancer Survivors N/A
Completed NCT02970682 - SFX-01 in the Treatment and Evaluation of Metastatic Breast Cancer Phase 2
Completed NCT02316561 - Single Dose Ablative Radiation Treatment for Early-Stage Breast Cancer N/A
Terminated NCT00638963 - Temozolomide as a Prophylaxis Against Brain Recurrence in Participants With Metastatic Breast Cancer (P05225 AM2) Phase 2
Terminated NCT00249301 - A Study of MLN8054 in Patients With Advanced Solid Tumors Phase 1
Not yet recruiting NCT06056414 - Study of Anxiety After a Session of Energy Resonance by Cutaneous Stimulation N/A
Recruiting NCT05427071 - Magnetic Marker Localization for Occult Breast Cancer and Target Axillary Dissection in Node-positive Breast Cancer Post-neoadjuvant Chemotherapy N/A
Recruiting NCT03740893 - PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition and/or Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Chemotherapy Resistant Residual Triple Negative Breast Cancer Phase 2